

For downloadable educational resources, visit below:

- [Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma \(RRMM\)](#)
- [Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study](#)
- [Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety](#)
- [Risk Evaluation and Mitigation Strategy \(REMS\) Document BLENREP \(belantamab mafodotin\) REMS Program](#)
- [The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma](#)
- [Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma](#)
- [“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience](#)
- [KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma](#)
- [Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy](#)
- [Patient experience before and after treatment with idecabtagene vicleucel \(ide-cel, bb2121\): qualitative analysis of patient interviews in the KarMMa trial](#)
- [Toxicity management strategies for next-generation novel therapeutics in multiple myeloma](#)
- [Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma](#)
- [Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies](#)

For a full list of all the educational tools available through Vindico Medical Education, please visit www.VindicoCME.com/educationaltools.